Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC0058TA in Systemic Lupus Erythematosus
NCT03878303Phase 1Unknown
- Sponsor
- ACEA Therapeutics
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing AC0058TA with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 12 weeks. Status: unknown.
02
Drugs
AC0058
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03878303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878303.